Reynders McVeigh Capital Management LLC Has $10.61 Million Stock Position in Novartis AG (NYSE:NVS)
Reynders McVeigh Capital Management LLC Has $10.61 Million Stock Position in Novartis AG (NYSE:NVS)
Reynders McVeigh Capital Management LLC grew its position in Novartis AG (NYSE:NVS – Get Rating) by 1.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 139,608 shares of the company's stock after buying an additional 2,387 shares during the period. Reynders McVeigh Capital Management LLC's holdings in Novartis were worth $10,612,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Activest Wealth Management acquired a new position in shares of Novartis in the 3rd quarter valued at $26,000. Carolinas Wealth Consulting LLC lifted its position in Novartis by 146.7% in the 2nd quarter. Carolinas Wealth Consulting LLC now owns 370 shares of the company's stock valued at $31,000 after acquiring an additional 220 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its position in Novartis by 42.7% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 441 shares of the company's stock valued at $34,000 after acquiring an additional 132 shares in the last quarter. Curi Wealth Management LLC bought a new stake in Novartis in the 2nd quarter valued at $46,000. Finally, Adirondack Trust Co. lifted its position in Novartis by 327.7% in the 3rd quarter. Adirondack Trust Co. now owns 556 shares of the company's stock valued at $42,000 after acquiring an additional 426 shares in the last quarter. Institutional investors and hedge funds own 8.12% of the company's stock.
Get Novartis alerts:Novartis Stock Performance
NYSE:NVS traded down $2.33 during mid-day trading on Thursday, reaching $85.90. 385,656 shares of the company's stock were exchanged, compared to its average volume of 2,160,289. Novartis AG has a one year low of $74.09 and a one year high of $94.26. The firm has a market capitalization of $190.06 billion, a PE ratio of 9.07, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52. The business's fifty day simple moving average is $90.68 and its two-hundred day simple moving average is $84.76. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.07 and a current ratio of 1.31.
Analysts Set New Price Targets
Several equities research analysts have commented on NVS shares. Barclays cut their price target on shares of Novartis from CHF 85 to CHF 75 in a research report on Friday, October 14th. StockNews.com started coverage on shares of Novartis in a research report on Wednesday, October 12th. They set a "strong-buy" rating on the stock. UBS Group boosted their price target on shares of Novartis from CHF 82 to CHF 84 and gave the stock a "neutral" rating in a research report on Wednesday, December 14th. Stifel Nicolaus raised shares of Novartis from a "hold" rating to a "buy" rating in a research report on Monday, December 5th. Finally, Morgan Stanley lowered shares of Novartis from an "equal weight" rating to an "underweight" rating in a research note on Friday, January 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $85.11.About Novartis
(Get Rating)
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals.
Read More
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
- Apple's Earnings, Expectations and Surprises
- T-Mobile Delivers Where it Matters Most to Investors
- Exxon Mobil Could Gush To New Highs Very Soon
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Get Rating).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
根據雷德斯麥克維資本管理有限責任公司提交給美國證券交易委員會的最新檔案,其在諾華製藥(紐約證券交易所代碼:NVS-GET評級)的頭寸在第三季度增加了1.7%。該公司持有139,608股該公司股票,在此期間又購買了2,387股。截至最近一個季度末,Reynders McVeigh Capital Management LLC持有的諾華股份價值10,612,000美元。
其他機構投資者和對沖基金最近也對他們在該公司的頭寸進行了調整。Activest Wealth Management在第三季度收購了價值2.6萬美元的諾華股票的新頭寸。Carolinas Wealth Consulting LLC在第二季度將其在諾華的頭寸提高了146.7%。Carolinas Wealth Consulting LLC現在持有該公司370股股票,價值3.1萬美元,上個季度又購買了220股。創新金融設計公司ADV在第三季度將其在諾華的頭寸提高了42.7%。Creative Financial Designs Inc.ADV在上個季度增持了132股後,現在持有441股該公司股票,價值3.4萬美元。Curi Wealth Management LLC在第二季度購買了諾華的新股份,價值4.6萬美元。最後,阿迪朗達克信託公司在第三季度將其在諾華的持倉提高了327.7%。Adirondack Trust Co.目前持有該公司556股股票,價值42,000美元,上一季度又購入了426股。機構投資者和對沖基金持有該公司8.12%的股票。
到達諾華公司警報:諾華公司股票表現
紐約證券交易所:NVS週四午盤交易中下跌2.33美元,至85.90美元。該公司股票成交量為385,656股,而其平均成交量為2,160,289股。諾華製藥的一年低點為74.09美元,一年高位為94.26美元。該公司的市值為1900.6億美元,本益比為9.07倍,本益比為2.17倍,貝塔係數為0.52倍。該業務的50日簡單移動均線切入位為90.68美元,200日簡單移動均線切入位為84.76美元。該公司的負債權益比率為0.32,速動比率為1.07,流動比率為1.31。
分析師設定新的價格目標
幾位股票研究分析師對NVS的股票發表了評論。巴克萊銀行在10月14日星期五的一份研究報告中將諾華公司的股票目標價從85瑞士法郎下調至75瑞士法郎。StockNews.com在10月12日星期三的一份研究報告中開始報道諾華的股票。他們對該股設定了“強力買入”評級。瑞銀集團在12月14日星期三的一份研究報告中將諾華公司的股票目標價從82瑞士法郎上調至84瑞士法郎,並給予該股“中性”評級。Stifel Nicolaus在12月5日星期一的一份研究報告中將諾華公司的股票評級從持有上調至買入。最後,摩根士丹利在1月6日星期五的一份研究報告中將諾華公司的股票評級從“持平”下調至“減持”。三位分析師對該股的評級為賣出,七位分析師給出了持有評級,三位分析師給出了買入評級,一位分析師對該公司給予了強烈的買入評級。根據MarketBeat.com的數據,該股目前的平均評級為持有,平均目標價為85.11美元。諾華公司簡介
(獲取評級)
諾華製藥是一家控股公司,從事保健品的開發、製造和營銷。它通過以下細分市場運作:創新藥物、Sandoz和公司。創新藥品部門研究、開發、製造、分銷和銷售專利藥品,由兩個業務部門組成:諾華腫瘤和諾華製藥。
閱讀更多內容
- 免費獲取StockNews.com關於諾華(Novartis)的研究報告
- Meta平臺的底部已經到了,波動性還沒有結束
- 阿拉斯加航空公司近期收益分析
- 蘋果的收益、預期和驚喜
- T-Mobile在對投資者最重要的領域提供服務
- 埃克森美孚可能很快創下新高
想看看其他對沖基金持有哪些NVS嗎?訪問HoldingsChannel.com獲取諾華製藥(紐約證券交易所代碼:NVS-GET Rating)的最新13F檔案和內幕交易資訊。
接受諾華日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對諾華和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧